PharmaCyte Biotech, Inc. (PMCB)

Company Overview
Nuvilex is an innovative company which aims at ionitiating a paradigm shift, generating revenue at the same time as creating cancer and other cell related solutions to treat important human diseases, such as pancreatic cancer while retaining our connections to natural products. The present effort underway will give rise to dramatic advances in cancer therapy and benefit millions of people worldwid
read more

Watch the video to learn about the probability of PharmaCyte Biotech, Inc. (PMCB) Chart Signal as of Jan 31, 2015

Hotstocked Precision will calculate the probabilities of PharmaCyte Biotech, Inc. (PMCB)

Rating:
Size: 656KB
Version: 1.1
Platform: Win/Mac
Downloads: 800,000+
FREE DOWNLOAD

QUOTE

As of 02:03AM EST January 31, 2015
$ 0.1077   -0.01 (-4.69%)
Today's Open: 0.1175 Previous Close: 0.113
Today's High: 0.118 Volume: 5,914,290
Today's Low: 0.095 Avg Vol: 2,568,331
52 Week High: 0.62 Bid (size): 0
52 Week Low: 0.095 Ask (size): 0

COMPANY INFO

To see the headquarters in Google Street View &trade, drag this yellow guy: over to the red pointer:

Contact Information:

Business Address: Meadows Corporate Park I, 12510 Prosperity Boulevard, Silver Spring, MD 20904, United States
Mailing Address: -
Phone: 240-696-6859
Fax: -
Website: http//www.nuvilex.com

Company Details:

Symbol: PMCB
SIC: -
State location: MD
Sector: -
State of Inc: NV
Employees: 1
Type: -

Key executives:

Name Age Position
2015
Dr. Gerald W. Crabtree 2015 COO
Patricia Gruden 2015 Chairman of the Board of Directors and CFO
Robert F. Ryan 2015 President, CEO

Watch the video to learn about the probability of PharmaCyte Biotech, Inc. (PMCB) Chart Signal as of Jan 31, 2015

This free program will calculate the probabilities of PharmaCyte Biotech, Inc. (PMCB) stock chart

Rating: Platform: Win/Mac
Price: FREE Version: 1.1
Size: 656KB Downloads: 800,000+
FREE DOWNLOAD

LATEST ARTICLES

Pharmacyte Biotech, Inc. (OTCMKTS:PMCB) Slides Further Down January 30, 2015

Yesterday brought Pharmacyte Biotech, Inc. (OTCMKTS:PMCB) another 9.60% fall and with it – yet another 52 week low. read more

Pharmacyte Biotech, Inc. (OTCMKTS:PMCB) Still Wriggling Under Pumps January 28, 2015

Amazingly, someone is still paying promoters to tout the stock of Pharmacyte Biotech, Inc. (OTCMKTS:PMCB). The ticker has been showered with promotional emails almost non-stop since January 19 and it shows – PMCB is currently over 20% down from its pre-... read more

PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) Sails to New 52-Week Low January 23, 2015

After a couple of troubled weeks on the charts, yesterday the share price of PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) slid and hit a new 52-week low at $0.134. Nearly 9 million PMCB shares changed hands as heavy selling pushed the price over 13% down. read more

Small-Time Pump for PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) Continues January 13, 2015

After a single drive-by paid email tout targeted the stock of PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) last Thursday, yesterday another email filtered through. The new tout came after the markets had closed, with PMCB 4% in the red, at $0.178 per share. read more

LATEST STOCK PROMOTIONS

PMCB - Tues Alert: Reports Pre-Clinical Study Starts In 2 Weeks Jan 27, 2015, 08:02

    FOR: Tuesday, January 27, 2015   OTC: PMCB         PharmaCyte Biotech, Inc. (PMCB)         Attention Traders!     As A Reminder Our New Pick For Tuesday Is:  PMCB     If you have been a member for a while now, you probably already know that some of our biggest gains ever have been biotech picks that have absolutely soared just read more

Promoter: Penny Pick Finders Paying Party: Cream Consulting Max Profit: 0.71% Gain at close: Pending
Stock: pmcb Compensation: $15,000 Avg $ Volume for Period: UNKNOWN

PMCB's pancreatic cancer treatment granted orphan drug designation... Jan 26, 2015, 19:07

PharmaCyte Biotech, Inc. (PMCB) PharmaCyte Biotech, Inc. (PMCB), formerly Nuvilex, Inc., is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. This technology will be used as a platform upon which treatments read more

Promoter: PST Alerts Paying Party: Galaxy LLC Max Profit: 0.71% Gain at close: Pending
Stock: pmcb Compensation: $5,000 Avg $ Volume for Period: UNKNOWN

PMCB's pancreatic cancer treatment granted orphan drug designation... Jan 26, 2015, 19:05

PharmaCyte Biotech, Inc. (PMCB) PharmaCyte Biotech, Inc. (PMCB), formerly Nuvilex, Inc., is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. This technology will be used as a platform upon which treatments read more

Promoter: Buzz Stocks Paying Party: Galaxy LLC Max Profit: 0.71% Gain at close: Pending
Stock: pmcb Compensation: $5,000 Avg $ Volume for Period: UNKNOWN

Nuvilex, Inc. (NVLX) MESSAGE BOARD

Post # Subject Re Name Date
1 Such a deep anewsr! GD&RVVF 0
2 I love these areltics. How many words can... 0
3 Well, I think the Fed has to do a lot... 0
4 I just love how optimistic Jim Cramer and... 0
5 Dear Minamar,Can you give me some more... 0
6 Well mamiadcaa nuts, how about that. 0
7 I hope so 0
8 I'm a Dollarniare now! The scams on otc... 0
9 yes we are ging to be millionaires but it... 1
10 chemo kills weed does not 0
11 What happened to this stock today? It's... 0
12 Oh what happened? 2
13 Tanking like a ROCK!! Alpha Articles out!!! 4
14 FDA possible approval response to NVLX... 1
15 Yes it can 0
16 Man! I'd personally write some options... 0
17 20 Ducats? You jest my dear buffoon! 0
18 Oh Sheeheeheeheet! NVLX is fo' real ?... 0
19 50:1 split? Ha ha 0
20 with a 50:1 Reverse stock split! Yes... 0